A fact-based media briefing about bipolar disorder in Nova Scotia Around 26.

Who: Phil Upshall, National Executive Director of the Feeling Disorders Culture of Canada and adjunct professor with the Department of Psychiatry at Dalhousie University . Dr. Claire O’Donovan, Psychiatrist, Feeling Disorders, Capital District Mental Health Associate and Applications Professor with the Department of Psychiatry in Dalhousie University. Nancy Beck, faculty member of the Section of Psychiatry, International Psychiatry Division at Dalhousie University and Director of Connections Halifax. Susan Kilbride Roper, who lives with Bipolar Disorder.. A fact-based media briefing about bipolar disorder in Nova Scotia Around 26,000 Nova Scotians live with bipolar disorder.Co-promotion provides ARIAD with a primary involvement in the potential industrial achievement of ridaforolimus and, simultaneously, lays the groundwork for the infrastructure which will be employed by ARIAD for the potential future commercialization of ponatinib upon approval. Interim Data from the Speed Trial Expected at End of Yr Patient enrollment is nearly total in the pivotal Stage 2 Speed trial of ponatinib, ARIAD’s investigational pan-BCR-ABL inhibitor, with five of six patient cohorts now closed to enrollment and the sixth likely to close this one fourth. The global PACE trial has been conducted in individuals with persistent myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia who are resistant or intolerant to either of the second-generation CML treatments, or those who have the T315I mutation of BCR-ABL that no current remedies are known to be effective.